Across TCGA pan-cancer cohorts, ZBTB45 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ZBTB45 data layer compared with 24 for mass-spec protein and 4 for mutation status.
The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher ZBTB45 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ZBTB45 expression acts as an unfavorable survival marker, although some lineages such as LSCC and CCRCC show a favorable association.
LSCC, UCEC, and CCRCC are the cancer types where ZBTB45 mass-spec protein most reproducibly stratifies survival.